Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Suprachoroidal triamcinolone acetonide injection.
- Who it may be relevant to
- Registry conditions: Macular Edema (ME), Non Infectious Uveitis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Iraq
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this study is to learn if a suprachoroidal triamcinolone injection can treat vision-threatening swelling in the center of the retina (macular edema) caused by non-infectious uveitis, especially in people who did not improve after a standard steroid injection around the eye (sub-Tenon injection). The main questions it aims to answer are: Does vision improve on the eye chart after the injection? Does the injection lower retinal swelling (reduction in thickness) within 3 months? Participants will: Have a pre-treatment check (vision test, slit-lamp exam, and a retinal scan called OCT). Receive one suprachoroidal triamcinolone injection under anesthetics drops in a sterile setting (operating room) with standard monitoring. Return for visits about 1 month and 3 months after treatment for repeat vision tests, and OCT scans. Contact the clinic if they notice pain, redness, new floaters, or worsening vision.
Interventions
- Drug Suprachoroidal triamcinolone acetonide injection
For suprachoroidal injection, we developed a custom-made delivery system to access the potential suprachoroidal space. A 1 mL tuberculin syringe fitted with a 27-gauge needle was prepared, and a plastic sleeve from a 24-26 G IV cannula was placed over the needle as a spacer to control penetration depth.
Primary outcome measures
- Visual acuity improvement [Time frame: 3 months]
Secondary outcome measures (1)
- Central Macular Thickness [Time frame: 3 Months]
Eligibility criteria
Inclusion criteria
- Non-infectious uveitis complicated with macular edema
- Uveitic macular edema of less than four months' duration
- Macular edema persisted despite lack of intra-ocular inflammation
- No response to posterior sub-Tenon triamcinolone acetonide injections
Exclusion criteria
- Those with epiretinal membrane-associated macular edema
- Below 18 years
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Iraq · 1 center
- Ibn Al-Haitham Eye Teaching Hospital — Baghdad
Identifiers
NCT: NCT07145008 · 2024-234